Discounts represent out-of-pocket costs and come in the form of direct-to-consumer sales through manufacturer websites or via a coupon. AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk and Pfizer have all listed some of their most popular drugs on the TrumpRx.gov portal.

The Federal Trade Commission was suing the pharmacy benefit manager over allegations it was deliberately inflating the price of insulin. Per the agreement, Express Scripts has agreed to end business practices that involved taking manufacturer rebates on wholesale drug costs without passing them on to patients.

A surgeon and a medical device representative accuse Portneuf Medical Center of failing to address an ongoing problem with contaminated surgical tools that left patients with serious infections.

The Federal Trade Commission said it's seeking a resolution with Cigna, the parent company of the pharmacy benefit manager. The agency filed an antitrust complaint against Express Scripts, Optum Rx and CVS Caremark in 2024, alleging the "Big Three" PBMs use anticompetitive tactics to control the insulin supply chain within their vertical.

The third round of the Medicare Drug Price Negotiation Program includes treatments for HIV and diabetes, among other conditions. The Centers for Medicare & Medicaid Services also released a list of the top 50 medications it deems strong candidates for future negotiations based on current prices and patient utilization.

The Missouri complaint mirrors those brought by the Federal Trade Commission, the state of Texas and Philadelphia-based Jefferson Health, among others, in that it’s focused on alleged collusion between pharmacy benefit managers and drug companies to control the price of insulin. 

Vapor 2000 and Vapor 3000 devices manufactured by Draegar were improperly cleaned after parts were soldered on, meaning toxic metals could mix with medical gases. Due to the high risk posed to patient health, this recall has earned the FDA’s most serious designation. 

Boston Scientific sent all known customers a letter on December 19, 2025 alerting them to an issue with certain AXIOS Stent and Electrocautery Enhanced Delivery Systems. During deployment, the stents may not expand. This can cause severe, potentially life-threatening injury to patients. All recalled stents must be removed from clinical settings immediately.